Johnson and Johnson to Pay $3B to Acquire Halda Therapeutics

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada.

At the center of the acquisition is Halda’s regulated induced proximity targeting chimera (RIPTAC) platform, which gives rise to bifunctional small molecules that simultaneously bind a tumor-specific protein and a protein with essential function to cell survival in efforts to induce cancer cell death.

Read more at Fierce Biotech